SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials
Study context
- Population
- Adults with severe obesity (BMI ≥ 40 kg/m² with ≥1 treated obesity-related complication) treated with semaglutide 2.4 mg, 11 expert obesity centers in France; subgroups: prior bariatric surgery, binge eating disorder, hypothalamic obesity, age ≥ 60 years or altered body composition, BMI ≥ 60 kg/m², psychotropic medications
- Participants
- 1,100 adults11 centers
- Primary endpoint
- Body weight change since treatment initiation
- Follow-up
- 6 and 12 months
Methodological detailsmulticentric, embedded within the French early-access program, prospectively collected data
- Multicentric
- Embedded within the French early-access program
- Prospectively collected data
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials. Diabetes Obes Metab. Published 26 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →